GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (UKEX:MRK) » Definitions » Cyclically Adjusted PS Ratio

Merck (UKEX:MRK) Cyclically Adjusted PS Ratio : 6.42 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Merck Cyclically Adjusted PS Ratio?

As of today (2024-05-24), Merck's current share price is ₴4844.00. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₴754.78. Merck's Cyclically Adjusted PS Ratio for today is 6.42.

The historical rank and industry rank for Merck's Cyclically Adjusted PS Ratio or its related term are showing as below:

UKEX:MRK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.17   Med: 4.34   Max: 6.58
Current: 6.37

During the past years, Merck's highest Cyclically Adjusted PS Ratio was 6.58. The lowest was 3.17. And the median was 4.34.

UKEX:MRK's Cyclically Adjusted PS Ratio is ranked worse than
86.69% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.115 vs UKEX:MRK: 6.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck's adjusted revenue per share data for the three months ended in Mar. 2024 was ₴249.003. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₴754.78 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merck Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Merck's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Cyclically Adjusted PS Ratio Chart

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.39 4.79 4.39 5.85 5.44

Merck Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.48 5.85 5.14 5.44 6.42

Competitive Comparison of Merck's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.



Merck Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Merck's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4844.00/754.78
=6.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Merck's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=249.003/131.7762*131.7762
=249.003

Current CPI (Mar. 2024) = 131.7762.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 148.887 100.560 195.106
201409 145.630 100.428 191.088
201412 145.848 99.070 193.998
201503 132.102 99.621 174.741
201506 137.869 100.684 180.444
201509 142.628 100.392 187.217
201512 145.769 99.792 192.488
201603 133.787 100.470 175.474
201606 141.734 101.688 183.671
201609 151.861 101.861 196.461
201612 146.371 101.863 189.355
201703 136.961 102.862 175.460
201706 144.895 103.349 184.750
201709 152.040 104.136 192.396
201712 153.461 104.011 194.426
201803 148.726 105.290 186.140
201806 155.873 106.317 193.199
201809 161.854 106.507 200.255
201812 167.668 105.998 208.444
201903 166.857 107.251 205.013
201906 182.471 108.070 222.499
201909 193.552 108.329 235.444
201912 65.107 108.420 79.132
202003 190.091 108.902 230.020
202006 148.100 108.767 179.429
202009 172.918 109.815 207.499
202012 173.014 109.897 207.459
202103 167.941 111.754 198.029
202106 180.260 114.631 207.221
202109 208.286 115.734 237.156
202112 214.182 117.630 239.941
202203 251.684 121.301 273.419
202206 230.708 125.017 243.182
202209 236.308 125.227 248.668
202212 217.959 125.222 229.367
202303 228.045 127.348 235.975
202306 237.790 128.729 243.419
202309 251.757 129.860 255.473
202312 231.202 129.419 235.412
202403 249.003 131.776 249.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merck  (UKEX:MRK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Merck Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Merck's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (UKEX:MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (UKEX:MRK) Headlines

From GuruFocus

Merck & Co Inc Investor Event at ASCO 2023 Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024